RCT: Ustekinumab vs. adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn’s disease.

Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn’s disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial – The Lancet (link to abstract – $ for full-text)

Commentary on Twitter

New @TheLancet – Sands et al – Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease (SEAVUE trial)https://t.co/Ov9ahRTQuC#IBD #GITwitter #Crohnsdisease pic.twitter.com/5f3vI6rRKd

— The Lancet Gastroenterology & Hepatology (@LancetGastroHep) June 10, 2022